News
Orion Corporation and Glykos Finland Oy today announced that they have extended their research collaboration and licensing agreement for the development of next-generation antibody-drug conjugates (ADCs).
Read more...UCB, a global biopharmaceutical company focused on improving the lives of people with severe diseases, today announced plans for a significant investment in a new, state-of-the-art biologics manufacturing facility in the United States.
Read more...IXCells Biotechnologies USA, Inc. (“iXCells”), a leading cell technology company specializing in the generation of predictive human disease models is pleased to announce the launch of its modular iPSCore™ platform.
Read more...Simtra BioPharma Solutions, a leading contract development and manufacturing organization (CDMO) specializing in sterile injectables, today announced that it has formed a five-year strategic alliance with the Life Science business
Read more...Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the U.S. Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) for Zepzelca® (lurbinectedin) in combination
Read more...Swedish biotech company Salipro Biotech AB today announced that it has entered into a research collaboration with Daewoong Pharmaceutical Co., Ltd. Daewoong Pharmaceutical gains access to Salipro Biotech's expertise
Read more...Medicovestor, Inc., a New York-based biotechnology company pioneering first-in-class chemoimmunotherapy antibody-drug conjugates (ADCs) today announced a strategic partnership with Sanyou Biopharmaceuticals
Read more...Mission Bio, a leader in single-cell multiomics solutions for precision medicine, today announced the launch of its Tapestri® Genome Integrity CNV Solution. This new product is the only single-cell high-throughput solution
Read more...Elpis Biopharmaceuticals, a clinical-stage cell therapy company developing bispecific armored CAR-T therapies for solid tumors, today announced entry into a research collaboration agreement with Singapore General Hospital
Read more...Telix Pharmaceuticals Limited today announces that its prostate cancer PET[1] imaging agent, Illuccix® (kit for the preparation of gallium-68 gozetotide injection), has been granted marketing authorization in Germany by BfArM[2] for the detection and localization of prostate-specific membrane antigen
Read more...